News
Charles River Launches Novel IgY-based ELISA Kit for the Detection and Quantitation of Residual Host Cell Protein
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its first Enzyme-Linked Immunosorbent Assay (ELISA) Kit for the detection and quantitation of residual host
Chemed To Report Fourth-Quarter 2022 Earnings February 23, Related Conference Call To Be Held On February 24
Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the fourth quarter ended December 31, 2022, on Thursday, February 23, 2023, following the close of trading
Charles River Laboratories Schedules Fourth-Quarter 2022 Earnings and 2023 Guidance Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2022 financial results and provide 2023 guidance on Wednesday, February 22nd, before the market
Xencor to Present at the SVB Securities Global Biopharma Conference
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that
Premier, Inc. Reports Fiscal-Year 2023 Second-Quarter Results
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal year 2023 second quarter ended December 31, 2022. The
Charles River Laboratories Acquires SAMDI Tech
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired SAMDI Tech, Inc, a leading provider of high-quality, label-free high-throughput screening (HTS)
Premier, Inc. Declares Quarterly Cash Dividend
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common
Novocure Announces Organizational Changes to Prepare for Future Growth
Novocure (NASDAQ: NVCR) today announced organizational changes to prepare for future growth, effective Jan. 17.
Pritesh Shah, Novocure’s Chief Commercial Officer, will transition into a new
Charles River and Rznomics Announce RNA-based Anticancer Gene Therapy Manufacturing Alliance
Charles River Laboratories International, Inc. (NYSE: CRL) and Rznomics Inc., a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, today
Charles River Launches CliniPrime Suite of GMP-Compliant Cellular Products
Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of their new CliniPrimeTM suite of Good Manufacturing Practice (GMP)-compliant cellular starting materials
Charles River Establishes eXpDNA™ Plasmid Manufacturing Platform to Expedite DNA Programs
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its eXpDNA™ plasmid platform, established from the Company’s contract development and manufacturing (CDMO)
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10th, at 10:30 a.m. PST
Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023
Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update
Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 2022. Novocure is a global oncology company
Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
Novocure (NASDAQ: NVCR) today announced the LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival over standard
Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that
Acadia Healthcare to Present at the 41st Annual J.P. Morgan Healthcare Conference
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present at the 41st Annual J.P. Morgan Healthcare Conference, January 9-12, 2023, at The Westin St. Francis, San
Premier, Inc. to Report Fiscal 2023 Second-Quarter Results and Host Conference Call on February 7, 2023
Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2023 second quarter on Tuesday, February 7, at approximately 6:30 a.m. EST. The company will also
Premier Inc. to Participate in 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
Premier Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that members of its management team will participate in the 41st Annual J.P. Morgan
Novocure to Participate in 41st Annual J.P. Morgan Healthcare Conference
Novocure (NASDAQ: NVCR) announced today it will participate in the 41st Annual J. P. Morgan Healthcare Conference on January 10-11, 2023. William Doyle, Novocure’s Executive Chairman, will speak on
Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Acadia Healthcare Provides Business Outlook Ahead of Investor Day
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) will host its first Investor Day beginning at approximately 9:00 a.m. Eastern Time today, Wednesday, December 7, 2022, in New York City.
During the
Charles River Laboratories Adds Craig B. Thompson, M.D. to Board of Directors
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the re-appointment of Craig B. Thompson, M.D., former President and Chief Executive Officer, Memorial Sloan-Kettering
Charles River Launches Endosafe Nexus 200, Emphasizes Critical Importance of Smart Automation for Endotoxin Detection
Charles River Laboratories International, Inc. (NYSE: CRL) launches the Endosafe® Nexus 200™, expanding its robust endotoxin testing portfolio. The Nexus 200 is the next evolution of Charles
Maple Heights Behavioral Health Hosts Ceremony to Celebrate Grand Opening
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced its newest operating joint venture hospital, Maple Heights Behavioral Health, located in Fort Wayne, Indiana, and held a ribbon-tying